

## Confirmed Speakers

### Confirmed Speakers

#### **QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases**



Dr Atwood CHEUNG  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

#### **The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis**



Dr Andrew DILGER  
(BRISTOL-MYERS SQUIBB, Princeton, United States)

#### **First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases**



Dr Riccardo GIOVANNINI  
(BOEHRINGER INGELHEIM, Biberach, Germany)

#### **Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other**



Dr Uwe GRETH  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

#### **The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations**



Dr Wooseok HAN  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)

#### **Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH**



Dr Naoyoshi NOGUCHI  
(SCOHIA PHARMA, INC., Fujisawa, Japan)

#### **Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma**



Dr Matthew W. D. PERRY  
(ASTRAZENECA, Gothenburg, Sweden)

#### **Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy**



Dr Norbert SCHMEES  
(BAYER PHARMACEUTICALS, Berlin, Germany)

## Confirmed Speakers

---

### **GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)**



Dr Fredrik ZETTERBERG  
(GALECTO BIOTECH, Gothenburg, Sweden)